Selected highlights of ECTRIMS – ACTRIMS 2017
Paris, France – 25-28 October 2017
34 slides
Click here to download the ECTRIMS 2017 Slide Deck
Scientific review:
Dr. Daniel Selchen, Chief of Neurology, St. Michael’s Hospital, Toronto, Canada
Neurology
ECTRIMS 2017 DAILY REPORT – SATURDAY EDITION
October 28, 2017ECTRIMS 2017 DAILY REPORT – FRIDAY EDITION
October 27, 2017ECTRIMS 2017 DAILY REPORT – THURSDAY EDITION
October 26, 2017Cladribine: intermittent immunosuppression in MS
September 21, 2017SPECIAL REPORT
The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.